Sarepta Therapeutics

-$1.12 (-1.7%)
Closing price January 21, 2022
Tuesday’s top analyst upgrades and downgrades included Bilibili, Carvana, Crocs, GameStop, Goldman Sachs, Nike, Sarepta Therapeutics, Vir Biotechnology and Weber.
Friday afternoon's analyst upgrades and downgrades included BigCommerce, Citrix, GlaxoSmithKline, Nikola, Regeneron, Shake Shack and more.
Wednesday’s top analyst upgrades and downgrades included Alcoa, Caesars Entertainment, Chevron, DraftKings, Lucid, Sarepta Therapeutics, SoFi Technologies and Wynn Resorts.
Thursday’s top analyst upgrades and downgrades included Avis Budget, Chewy, Danaher, Eli Lilly, Etsy, Fastly, Halliburton, Robinhood, Roku, Walmart and Western Digital.
Tuesday’s top analyst upgrades and downgrades included Campbell Soup, Exact Sciences, Exelixis, Pool, Spirit Airlines and ZTO Express.
Monday's top analyst upgrades and downgrades included Best Buy, Discover Financial, Dollar General, Etsy, HCA Healthcare, KeyCorp, Simon Property, ViacomCBS and Weyerhaeuser.
Friday's top analyst upgrades and downgrades included Aflac, CME, Chevron, CVS Health, D.R. Horton, Goodyear Tire and Rubber, Lam Research, Micron Technology and U.S. Steel.
Tuesday's top analyst upgrades and downgrades included Crocs, Gap, GW Pharmaceuticals, Lowe's Companies, Merck, Nio, Palo Alto Networks, Phillips 66, Starbucks and Vital Farms.
Selecta Biosciences and Sarepta Therapeutics have announced that they had entered into a research license and option agreement.
Here are the biotech companies with exposure to experimental vaccines whose shares saw the biggest boost from this past week's coronavirus news.
China is facing an outbreak of the coronavirus, which may have spread to a few other countries in Asia. As a result, experimental vaccine stocks are skyrocketing.
Sarepta shares jumped last week on news that the company reached a licensing deal with Roche. While investors saw about a five-point bump from this news, one analyst sees much more upside for this...
Christmas Eve's top analyst upgrades, downgrades and initiations included Amgen, Apple, Builder FirstSource, CarMax, Dominion Energy, FedEx, Nike, Regeneron Pharmaceuticals and Sarpeta Therapeutics.
Sarepta Therapeutics shares made a handy gain to start the week after it announced a licensing agreement with Roche for its investigational gene therapy for Duchenne muscular dystrophy.
Sarepta shares jumped on Friday after the firm announced that the FDA has approved Vyondys 53 (golodirsen) for the treatment of Duchenne muscular dystrophy (DMD) in certain patients.